19:01 , Mar 15, 2019 |  BC Extra  |  Company News

Another setback for Spectrum's remaining pipeline after Rolontis BLA withdrawal

Spectrum said Friday that it withdrew a BLA for Rolontis eflapegrastim to treat chemotherapy-induced neutropenia. Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said it needs more time to provide additional manufacturing-related information to FDA, which was due before...
19:14 , Mar 14, 2019 |  BC Innovations  |  Emerging Company Profile

Silverback: Taking on tumoral myeloid cells

Silverback’s antibody-based conjugates stimulate innate and adaptive immunity by turning myeloid cells against tumors, while overcoming resistance to checkpoint inhibitors and other T cell-targeting immunotherapies. “When you are able to appropriately and potently activate myeloid...
18:42 , Mar 8, 2019 |  BC Extra  |  Company News

TNBC gets its first targeted agent with Tecentriq approval

The approval of Roche's Tecentriq atezolizumab to treat metastatic triple-negative breast cancer gives almost half of these patients and physicians' their first agent to treat a molecularly defined subgroup of patients with this fast-progressing cancer....
17:36 , Mar 8, 2019 |  BC Week In Review  |  Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions on March 1, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first...
00:27 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
18:24 , Mar 7, 2019 |  BC Innovations  |  Distillery Therapeutics

mir-515 inhibitor sensitizes HER2-negative breast and liver cancers to Kadcyla, Herceptin

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; liver cancer In vitro and cell culture studies suggest an inhibitor of miR-515 could sensitize HER2-negative breast and liver cancers to anti-HER2 therapies. Chemical synthesis and in vitro testing...
22:10 , Mar 1, 2019 |  BC Extra  |  Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions Friday, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first approved antidote...
19:56 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Guardant's liquid biopsy is faster, as effective as tissue biopsy

Guardant Health Inc. (NASDAQ:GH) said its Guardant360 liquid biopsy detected biomarkers at a similar rate as standard-of-care tissue genotyping tests, but faster. Data were presented at a media preview ahead of the American Association for...
02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
20:16 , Feb 21, 2019 |  BC Innovations  |  Emerging Company Profile

Refuge: Receptive CAR checkpoints

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety. CEO...